Raptor Pharmaceuticals Raises US$5 MillionNOVATO, California - Raptor Pharmaceuticals Corp. (”Raptor” or the “Company”) (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate US$5 million of gross proceeds through a private placement of units (”August 2009 Private Placement”) and through the exercise of warrants (the “Warrant Exchange”) originally issued in connection with its May/June 2008 private placement. The August 2009 Private Placement resulted in gross proceeds to Raptor of approximately US$2.4 million or US$2.3 million after placement agent fees and other expenses. The Warrant Exchange raised approximately US$2.6 million in net proceeds for Raptor. Vitol Tank Terminals International B.V. Enters a Joint Venture Agreement With MISC BerhadGENEVA - Vitol Tank Terminals International B.V. (”VTTI”), part of the Vitol Group, entered into a joint venture agreement today with MISC Berhad (”MISC”) to incorporate a joint venture company on an equal partnership basis. The joint venture company, Asia Tank Terminal Limited, will hold 100% equity interest in an oil terminal in Tanjung Bin, located in south-west Johor, Malaysia. Swiss Balsamic Vinegar Crystals at 3,000 Metres: New Investment Trend From Baerg MartiWOLLERAU, Switzerland - Top quality balsamic vinegar and vinegar crystals an asset: the Swiss company Baerg Marti is storing barrique barrels in the Alps for its investors. The first store was inaugurated on the Mutthorn on 15 August. New Consortium to Develop Drugs for Neglected Tropical DiseasesLEIDEN, The Netherlands - A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis, which affect millions of people worldwide. A total budget of nearly 3.6 million euros has been allocated over the next 4 years, to develop effective drugs for these diseases. The consortium includes IOTA Pharmaceuticals, Mercachem, Nycomed, the Drugs for Neglected Diseases initiative, the Royal Tropical Institute, the University of Bern, the VU University Amsterdam and TI Pharma. Cricket Stars Play on the JungfraujochINTERLAKEN, Switzerland - - The Cricketing World Elite Meet in the High Mountains for a Friendly Match on Snow - a Spectacle! Etinde Permit (Cameroon) Farm-in TransactionGENEVA - Vitol E and P Limited (VEP), part of the Vitol Group, is pleased to announce that it has entered into a farm-in agreement with Bowleven, the African focused oil and gas company, in respect of the Etinde Permit (Etinde, Cameroon). Nearly Half of Employed Executives Are Dissatisfied With Their Jobs, According to Korn/Ferry Executive QuizLOS ANGELES - - Results Also Reveal Lack of Trust of Managers and CEOs The most recent Executive Quiz results released today by The Korn/Ferry Institute reveal that nearly half (47 percent) of employed executives are either somewhat or very dissatisfied with their current position. The lackluster job market has not only left executives unhappy with their jobs, but survey results also uncover a lack of trust for corporate leadership. The Vitol Group Completes Expansion Projects at Two Key TerminalsGENEVA - The Vitol Group announced today the completion of two key projects in its storage and terminals business, VTTI (Vitol Tank Terminals International). Banco Bradesco Announces First Half 2009 Earnings ResultsSAO PAULO - Banco Bradesco S.A. (NYSE: BBD) announces First Half 2009 Earnings Results. EOS Five Nations Survey 2009HAMBURG, Germany - - European Payment Practices Companies in Switzerland and Germany benefit from their customers’ relatively high level of payment. This is one result from the EOS survey ‘European Payment Practices’: In cooperation with the independent market research institute Ipsos, the international EOS Group, a provider in the areas of information management, arrears management and receivables management, questioned 1200 companies in five European countries. Le Gruyere Premier Cru Wins Another International AwardDUDINGEN, Switzerland - At the International Cheese Awards 2009 in Nantwich (Cheshire, England) July 28/29th Von Muhlenen’s “Le Gruyere Premier Cru” was awarded “The Supreme Champion Overseas”, as previously won in 2006, from an array of entries from 24 different countries. Also, “Le Gruyere Premier Cru” won Gold in the Single Specialty Cheese Class and was awarded the LTS Litman Trophy. The cheese was then short-listed for the overall award of Nantwich Show Champion 2009; narrowly coming 2nd from a total of 2,761 entrants. Le Gruyere Premier Cru was also given the title of Reserve Champion to a British Stilton Cheese. Von Muhlenen won the following prizes: Ferring Donates US$3 Million to the Royal Textile Academy of BhutanSAINT PREX, Switzerland - Frederik Paulsen, Chairman of Ferring Pharmaceuticals, a pharmaceutical company with presence in all major European markets and in the US, announced a US$3 million donation to the Royal Textile Academy of Bhutan. This money will be used to fund the creation and development of a new cultural centre in the Bhutanese capital of Thimphu. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger AgreementNOVATO, California and LA JOLLA, California - - Nasdaq-Listed Biopharmaceutical Company Focusing on Improved Drug Targeting and Reformulation of Existing Therapeutic Compounds to Benefit Underserved Patient Populations Approval of Instanyl(R) Marks Important Turn in Management of Breakthrough Cancer PainTAASTRUP, Denmark - - First Intranasal Treatment for Breakthrough Cancer Pain Allowing Patients Fast, Effective and Good Tolerated Pain Relief Soon to be Available Weak Dollar and High Oil Prices in H1 Fail to Blight Syngenta’s OptimismLONDON - World-leading agri business Syngenta has pointed to strong levels of global demand for its products as it unveiled financial results for the first half of 2009. Ilaris(R) Recommended for European Approval as New Biologic Drug to Treat a Rare but Serious Group of Auto-Inflammatory DiseasesBASEL, Switzerland - - Not For US Media - Set to Become First Medicine in EU to Treat Patients Aged Four and Older Suffering From Life-Long Cryopyrin-Associated Periodic Syndrome (CAPS)(1) Merck Serono Submits Application for Cladribine Tablets as Multiple Sclerosis Therapy in EuropeGENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for Cladribine Tablets, Merck Serono’s proprietary investigational oral formulation of cladribine, as a therapy for patients with relapsing-remitting multiple sclerosis (MS). Cladribine Tablets could become the first orally administered disease-modifying therapy available for patients with MS, as all disease-modifying therapies currently approved for the treatment of MS are injectable. Qnective, Inc. (QNTV) Elects Another Top Specialist to its Board of Directors and as an OfficerZURICH, Switzerland - Qnective, Inc., a U.S. public company, headquartered in Zurich, Switzerland, has elected Mr. Valerio Camardella to its Board of Directors and as Chief Marketing Officer effective July 13, 2009. This appointment will provide Qnective with strong support in sales, marketing, and operations. Centile and Patton Team Up to Deliver Next-Generation Unified Communications for Large EnterprisesBERN, Switzerland - - Field-proven interoperability between IntraSwitch(c) VoIP application software and SmartNode(TM) VoIP gateways delivers convenient, cost-saving unified communications with rapid, trouble-free deployment for large businesses. Albis Technologies Achieves MEF-18 CertificationZURICH - Albis Technologies, the leading provider of circuit emulation solutions, has been awarded the MEF-18 certification for Circuit Emulation Services over Ethernet. GONAL-f Approved in Japan for Ovulation Induction in Infertile WomenGENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the Japanese Ministry of Health, Labor and Welfare has granted approval to extend the indication of GONAL-f(R) (follitropin alfa for injection) to infertile women suffering from irregular or no ovulation (oligoovulation or anovulation) due to a dysfunction in the hypothalamic- pituitary system or polycystic ovarian syndrome. GONAL-f is a recombinant follicle-stimulating hormone currently approved in Japan for the treatment of male infertility. Nord Stream and EU Energy Commissioner Reaffirm Importance of New Gas Supply RoutesZUG, Switzerland - - Nord Stream Will Provide Supply Route Diversification and Additional Gas From 2011 A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain DisordersTIRAT CARMEL, Israel - - Ten-Patient Feasibility Study Shows Safety and Potential for Non-Invasive Deep Brain Ablation World’s First Deep Brain Stimulation Device Approved for Treatment of Psychiatric Condition in EuropeTOLOCHENAZ, Switzerland - - CE Mark Approval for Medtronic’s Reclaim(R) DBS Therapy for Treatment of Chronic, Severe Obsessive-Compulsive Disorder Prospero Goes Live in SingaporeSINGAPORE - - Investment Bank Implements Core Banking Module in Asia SAGE, the rising publisher of banking solutions, is pleased to announce that a large international financial firm has gone live with Prospero’s core banking module for its Asia branches. The client is one of the leading investment banks in the world with a significant share of the Asian wealth management market. No Distance is Too Far: Top Manager at RapidShare Personally Presents 50,000 Euro Prize in IndiaCHAM, Switzerland - Cross reference: Picture is distributed via EPA (European Pressphoto Agency) and can be downloaded free of charge at: www.presseportal.de/pm/64910?keygroup=bild The Neuchatel Institute of Microengineering (IMT) of EPFL and BrightView Systems Announce Collaboration for Solar Cell Production Process Optimization SolutionsNEUCHATEL, Switzerland and PETACH-TIKVA, Israel - The Thin-Film Photovoltaics Laboratory at IMT, a world leading lab in silicon-based thin-film solar cells research, part of the renowned Ecole Polytechnique Federale de Lausanne (EPFL), and BrightView Systems, an innovative developer of production process optimization tools for the solar industry are joining forces to introduce novel solutions for the optimization of next generation thin-film solar cells production. Vale Plans to Offer Two Series of Mandatorily Convertible NotesRIO DE JANEIRO - Vale S.A. (NYSE: VALE, VALE.P) hereby announces that it plans to offer in the global capital markets two series of mandatorily convertible notes due 2012 (the Series VALE-2012 Notes and the Series VALE.P-2012 Notes) through its wholly-owned subsidiary Vale Capital II. At their maturity and upon certain events earlier, the Series VALE-2012 Notes will be mandatorily converted to American Depositary Shares (ADSs), each representing one common share of Vale, and the Series VALE.P-2012 Notes will be mandatorily converted to ADSs, each representing one preferred class A share of Vale. Together, the ADSs will represent up to an aggregate of 18,415,859 common shares and 47,284,800 preferred class A shares of Vale, all of which Vale currently holds in treasury. Is There a Wolf Inside Every Dog?GENEVA, Switzerland - Ever wondered why your dog continuously scents the air and the ground, enjoys running and chasing, loves the smell and taste of meat? Well the answer lies in his natural origins - a hunter, a carnivore that caught prey and ate meat - the wolf. Maybe it’s time to take a good look at your dog again, appreciate the wolf inside and feed as his nature intended. Merck Serono Launches “Global Fertility Academy” to Provide Education and Training for the Treatment of InfertilityGENEVA, Switzerland - - Global Fertility Academy Delivers Valuable Educational Tools Aiming at Increasing Expertise and Maximizing the Success Rate of Treatment Supportive Care in Cancer: Palonosetron Recommended 5-HT3 Antagonist for Emesis Prevention by MASCC/ESMOLUGANO, Switzerland - - Anticipated at the Rome 2009 MASCC International Symposium the Outcome of the 2009 Joint MASCC (Multinational Association for Supportive Care in Cancer)/ESMO (European Society of Medical Oncology) Antiemetic Guideline Update Meeting New important acknowledgment for palonosetron, the second generation 5-HT3 receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV). In April, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology on Antiemesis included palonosetron, as the “preferred” 5-HT3 antagonist in the combined regimen recommended for emesis prevention in patients undergoing highly emetogenic chemotherapy (HEC). Last week, MASCC (Multinational Association for Supportive Care in Cancer) and ESMO (European Society of Medical Oncology) decided to recommend palonosetron for the prevention of CINV induced by moderately emetogenic chemotherapy (MEC). The main outcome of MASCC/ESMO antiemesis guidelines, that will be published in July, has been released at the recent MASCC 2009 International Symposium held in Rome. MASCC/ESMO announced that the combined regimen palonosetron and multiday dexamethasone is recommended to prevent acute and delayed vomiting and nausea following the chemotherapy of moderate risk. DSwiss Launches DataInherit - The First Internet Data Safe With Data InheritanceZURICH, Switzerland - DSwiss AG, the Internet data banking specialists, announced today the launch of DataInherit (www.datainherit.com), a new and innovative global Internet service offering a high security data safe with a unique digital inheritance feature. Omega and the Lunar PioneersBIENNE, Switzerland - - The Speedmaster Reunites Four Moonwalkers It is one of the defining events in history: on the 21st of July 1969 at 02:56:20 GMT, Neil Armstrong stepped onto the Moon and was joined a few minutes later by Buzz Aldrin. For a brief moment in time, the Apollo 11 mission united people from all over the world in a way that nothing else ever had. Everyone of a certain age remembers exactly where they were when they heard the words, “The Eagle has landed.” 50th Anniversary of the Swiss Museum of Transport in LucerneLUCERNE, Switzerland - Switzerland’s most popular museum currently attracts more than 820,000 visitors a year and is celebrating its 50th anniversary. With the “VHS 2009″ investment project covering approximately 50 million Swiss francs, the management of the Swiss Museum of Transport launched and completed what might well be a record-breaking new building and attraction-enhancing programme with a long-term impact on both the premises and content of the museum. WISeKey Will Provide Digital Certification Services to the Cecilia Attias FoundationGENEVA, Switzerland - WISeKey will be providing Digital Certification Services and use of the HighTrusted Platform to the Cecilia Attias Foundation for Women www.ceciliaattiasfoundation.org/home which provides concrete improvement in the lives of women worldwide by serving as a strategic, media, and financial platform for organizations that champion the cause of women’s equality and well-being. |
